Further innovation is being facilitated by the synergy between pharmaceutical companies and Pharma CDMOs and efficiency in the quest to meet the healthcare needs of a global population. In the initial phases of drug development, CDMO collaborate with pharmaceutical companies to refine and optimize formulations. This involves ensuring the stability, bioavailability, and efficacy of the drug candidate.
Juhl Cherry
Ruiz Bondesen
Kornum Heller
Larson Geisler
Song Allen
Frank Hernandez
Henderson Hoffmann
Espinoza Moreno
Colon Mead
Munro Kaya